Iovance Biotherapeutics, Inc. IOVA EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s EBITDA margin?
- Iovance Biotherapeutics, Inc. (IOVA) reported EBITDA margin of -122.6% in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s EBITDA margin changed year-over-year?
- Iovance Biotherapeutics, Inc.'s EBITDA margin increased by 32.6% year-over-year, from -181.9% to -122.6%.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s EBITDA margin?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s EBITDA margin has grown at a -93.7% compound annual growth rate (CAGR), from -37,766.7% to -148.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.